Beta-blockade enhances anthracycline control of metastasis in triple-negative breast cancer
- 26 April 2023
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 15 (693) , eadf1147
Abstract
Beta-adrenergic blockade has been associated with improved cancer survival in patients with triple-negative breast cancer (TNBC), but the mechanisms of these effects remain unclear. In clinical epidemiological analyses, we identified a relationship between beta-blocker use and anthracycline chemotherapy in protecting against TNBC progression, disease recurrence, and mortality. We recapitulated the effect of beta-blockade on anthracycline efficacy in xenograft mouse models of TNBC. In metastatic 4T1.2 and MDA-MB-231 mouse models of TNBC, beta-blockade improved the efficacy of the anthracycline doxorubicin by reducing metastatic development. We found that anthracycline chemotherapy alone, in the absence of beta-blockade, increased sympathetic nerve fiber activity and norepinephrine concentration in mammary tumors through the induction of nerve growth factor (NGF) by tumor cells. Moreover, using preclinical models and clinical samples, we found that anthracycline chemotherapy up-regulated β2-adrenoceptor expression and amplified receptor signaling in tumor cells. Neurotoxin inhibition of sympathetic neural signaling in mammary tumors using 6-hydroxydopamine or genetic deletion of NGF or β2-adrenoceptor in tumor cells enhanced the therapeutic effect of anthracycline chemotherapy by reducing metastasis in xenograft mouse models. These findings reveal a neuromodulatory effect of anthracycline chemotherapy that undermines its potential therapeutic impact, which can be overcome by inhibiting β2-adrenergic signaling in the tumor microenvironment. Supplementing anthracycline chemotherapy with adjunctive β2-adrenergic antagonists represents a potential therapeutic strategy for enhancing the clinical management of TNBC.Keywords
This publication has 47 references indexed in Scilit:
- Increased Beta2-Adrenoceptors in Doxorubicin-Induced Cardiomyopathy in RatPLOS ONE, 2013
- NCBI GEO: archive for functional genomics data sets—updateNucleic Acids Research, 2012
- Adjuvant treatments for triple-negative breast cancersAnnals of Oncology, 2012
- Impaired Cognitive Function and Hippocampal Neurogenesis following Cancer ChemotherapyClinical Cancer Research, 2012
- Beta-Blocker Use Is Associated With Improved Relapse-Free Survival in Patients With Triple-Negative Breast CancerJournal of Clinical Oncology, 2011
- Increased Expression of P-Glycoprotein Is Associated with Doxorubicin Chemoresistance in the Metastatic 4T1 Breast Cancer ModelThe American Journal of Pathology, 2011
- The Sympathetic Nervous System Induces a Metastatic Switch in Primary Breast CancerCancer Research, 2010
- pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐upHistopathology, 1991
- Chronic Effects of Metoprolol on Myocardial β-Adrenergic Receptors in Doxorubicin-Induced Cardiac Damage in RatsJournal of Cardiovascular Pharmacology, 1991
- Effects of chronic administration of doxorubicin on myocardial beta-adrenergec receptorsLife Sciences, 1986